>Mercado de tratamiento del dengue en Oriente Medio y África, por cepas (DENV-1, DENV-2, DENV-3, DENV-4, otras), transmisión (transmisión de mosquitos a humanos y transmisión de madre a hijo), tipo (medicamentos, cuidados paliativos, vacunación y otros), gravedad (sin complicaciones y grave), vía de administración (oral y parenteral), modo de compra (con receta y sin receta (OTC)), usuario final (hospitales, clínicas especializadas, atención médica domiciliaria y otros), canal de distribución (farmacias hospitalarias, farmacias minoristas, farmacias en línea y otras), país ( Sudáfrica , Arabia Saudita, Emiratos Árabes Unidos, Egipto, Israel, resto de Oriente Medio y África), tendencias de la industria y pronóstico hasta 2028
Análisis y perspectivas del mercado: mercado de tratamiento del dengue en Oriente Medio y África
Se espera que el mercado de tratamiento del dengue gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 23,7% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 53,49 millones para 2028. Es probable que las iniciativas estratégicas de los actores del mercado y el advenimiento de programas de vacunación masiva para el tratamiento del dengue sean los impulsores clave del mercado de tratamiento del dengue.
El dengue es una enfermedad viral transmitida por mosquitos que se ha propagado rápidamente en todas las regiones de la OMS (Organización Mundial de la Salud) en los últimos años. El virus del dengue se transmite principalmente por mosquitos hembra del género Aedes aegypti y, en menor grado, por Ae. albopictus. Las enfermedades transmitidas por estos mosquitos vectores son el chikungunya, la fiebre amarilla y el virus del Zika. El dengue es frecuente en los trópicos, inducido por las precipitaciones, la temperatura , la humedad relativa y la rápida urbanización no planificada con variabilidad de riesgo local.
A pesar de las medidas controladas, el aumento global de la incidencia del dengue, junto con la mayor frecuencia de brotes localizados y el potencial de proliferación de las especies de Aedes conducen a un aumento en el consumo de la opción de tratamiento para el tratamiento del dengue y se espera que actúe como un impulsor del mercado de tratamiento del dengue. El costo del tratamiento del dengue es más alto, como se indica en la declaración anterior, y con más complicaciones relacionadas con el dengue, como la falla multiorgánica y otras, puede aumentar el costo total de los resultados de la terapia en la persona infectada para evitar terapias adecuadas para el tratamiento del dengue, lo que puede actuar como una restricción para el mercado de tratamiento del dengue. El dengue puede diagnosticarse tradicionalmente mediante pruebas serológicas, pero ahora con la actualización tecnológica, existen diferentes formas en curso y desarrolladas para la detección del virus, lo que creará una oportunidad para el mercado de tratamiento del dengue. El dengue es una enfermedad transmitida por vectores con medicamentos no específicos, como antipiréticos y algunos antibióticos, pero se espera que las medidas preventivas e iniciativas adoptadas por las diferentes agencias gubernamentales en todo el mundo actúen como un desafío para el mercado de tratamiento del dengue.
El informe del mercado de tratamiento del dengue proporciona detalles de la participación de mercado, los nuevos desarrollos y el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsas de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado de tratamiento del dengue, comuníquese con Data Bridge Market Research para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de tratamiento del dengue en Oriente Medio y África
El mercado de tratamiento del dengue está segmentado en función de las cepas, la transmisión, el tipo, la gravedad, la vía de administración, el modo de compra, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus principales áreas de aplicación y la diferencia en sus mercados objetivo.
- En función de las cepas, el mercado de tratamiento del dengue se segmenta en DENV-1, DENV-2, DENV-3, DENV-4 y otras. En 2021, el segmento DENV-2 domina el mercado, ya que esta cepa tiene una alta prevalencia, lo que da lugar a un mayor número de casos de infección por dengue. Aunque el dengue también puede ser causado por otras cepas, la complicación clínica más importante se observa en DENV-2.
- En función de la transmisión, el mercado de tratamiento del dengue se segmenta en transmisión de mosquito a humano y transmisión de madre a hijo. En 2021, el segmento de transmisión de mosquito a humano domina el mercado, ya que los mosquitos son el principal vector de transmisión del dengue para las diferentes cepas del virus. Cuando un mosquito pica a una persona infectada, también se infecta y el virus pasa a la sangre, y cuando vuelve a picar a otra persona, el virus se transmite a esa persona. Esta es la razón por la que la transmisión de mosquito a humano domina el mercado.
- Según el tipo, el mercado de tratamiento del dengue se segmenta en medicamentos , cuidados paliativos , vacunación y otros. En 2021, el segmento de medicamentos domina el mercado, ya que se han utilizado diversos medicamentos para tratar el dengue desde hace mucho tiempo.
- En función de la gravedad, el mercado de tratamiento del dengue se segmenta en sin complicaciones y grave. En 2021, el segmento sin complicaciones domina el mercado, la tasa de conversión de dengue sin complicaciones a dengue grave es inferior al 5%, lo que constituye la razón más importante por la que el segmento sin complicaciones domina el mercado de tratamiento del dengue.
- On the basis of route of administration, the dengue treatment market is segmented into oral and parenteral. In 2021, oral segment is dominating in the market as most of the drug that are taken to treat the symptoms of dengue are taken oral for pain management and fever management.
- On the basis of mode of purchase, the dengue treatment market is segmented into prescription and over the counter (OTC). In 2021, prescription segment is dominating in the market as the medication and the supportive care is prescribed by the doctor after the confirmation the patient is infected by the dengue virus and the treatment options consist of antibiotics and other medication which are generally not available as prescribed medication only.
- On the basis of end user, the dengue treatment market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, home healthcare segment is dominating in the market as the symptoms of dengue can be managed at home using medications such as pain relief and fever management drugs after the diagnosis.
- On the basis of distribution channel, the dengue treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the market as after proper diagnosis of dengue most of the prescriptions by patients are filled in retail pharmacies during the total duration of the treatment cycle of the infection.
Dengue Treatment Market Country Level Analysis
The dengue treatment market is analysed and market size information is provided by the country, strains, transmission, type, severity, route of administration, mode of purchase, end user and distribution channel as referenced above.
The countries covered in the dengue treatment market report are the South Africa, Saudi Arabia, UAE, Egypt, Israel & Rest of Middle East and Africa.
Middle East and Africa is expected to grow with the substantial growth rate in the forecast period of 2021 to 2028 as Middle East and Africa counties are major developing countries. South Africa is expected to dominate in the market in the Middle East and Africa due to growing focus on increasing R&D activities in pharma and biotech sector and increase outsourcing services.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Necessity of Dengue Treatment in Urban Areas and the Strategic Initiatives by Market Players are is Creating New Opportunities for Players in the Dengue Treatment Market
The dengue treatment market also provides you with detailed market analysis for every country growth in particular industry with dengue treatment sales, impact of advancement in the dengue treatment and changes in regulatory scenarios with their support for the dengue treatment market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Dengue Treatment Market Share Analysis
The dengue treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to dengue treatment market.
The major companies providing dengue treatment are Takeda Pharmaceutical Company Limited, Sanofi, EMERGEX VACCINES, ABIVAX, GlaxoSmithKline plc, Aurobindo Pharma USA, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Mylan N.V., Fresenius Kabi USA, Hikma Pharmaceuticals PLC, Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Baxter, Teva Pharmaceutical Industries Ltd. among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The strategic initiatives by market players with capital investment for dengue research are bridging the gap between dengue and its treatment in the dengue treatment market.
For instance,
- In November 2020, Viatris Inc. was launched as a combination of two Mylan N.V. and Pfizer Upjohn business. This combination of the two will focus on improving patient health. Viatris Inc. has the scientific production and distribution expertise with proven medical, regulatory and global commercial capabilities to provide high-quality medicines to patients in more than 165 countries and territories. This launch of a new company will increase the revenue of the company in near future.
La colaboración, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando el mercado de la empresa en el mercado de tratamiento del dengue, lo que también proporciona el beneficio para que la organización mejore su oferta para el mercado de tratamiento del dengue.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 STRAINS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 PIPELINE ANALYSIS
6 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: REGULATIONS
6.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT
6.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT
6.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK
6.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE
6.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK
7 CLINICAL STUDIES FOR DENGUE TREATMENT PRODUCTS.
7.1 SYNTHETIC DRUGS
7.2 BIOMARKER
7.3 DIRECT ACTING ANTIVIRAL DRUGS
8 EPIDEMIOLOGY
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASING INCIDENCE IN DENGUE CASES
9.1.2 ADVENT OF VACCINATION PROGRAMS
9.1.3 INCREASE IN RESEARCH AND DEVELOPMENT FUNDING
9.1.4 ROLE OF IGM AND IGG ANTIBODIES IN DENGUE
9.1.5 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES
9.2 RESTRAINTS
9.2.1 HIGH COST OF TREATMENT
9.2.2 DEARTH AWARENESS ABOUT THE SYMPTOMS OF DENGUE
9.2.3 LACK OR INSUFFICIENT HEALTHCARE INFRASTRUCTURE
9.3 OPPORTUNITIES
9.3.1 NEED FOR DENGUE TREATMENT IN URBAN AREAS
9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
9.3.3 TECHNOLOGICAL ADVANCEMENT IN DENGUE VIRUS DETECTION
9.3.4 INCREASE IN MIDDLE EAST AND AFRICA TRAVEL AND RELATION WITH DENGUE
9.4 CHALLENGES
9.4.1 PRESENCE OF PREVENTIVE MEASURES FOR DENGUE AND IT’S SPREAD
9.4.2 CHALLENGES IN DETECTION ASSAY FOR DENGUE
9.4.3 ALTERNATIVES FOR DENGUE TREATMENT
10 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET
10.1 IMPACT ON PRICE
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISION BY MANUFACTURERS
10.5 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
10.6 CONCLUSION
11 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS
11.1 OVERVIEW
11.2 DENV-3
11.3 DENV-2
11.4 DENV-1
11.5 DENV-4
11.6 OTHERS
12 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TRANSMISSION
12.1 OVERVIEW
12.2 MOSQUITO-TO-HUMAN TRANSMISSION
12.3 MOTHER-TO-CHILD- TRANSMISSION
12.4 OTHERS
13 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TYPE
13.1 OVERVIEW
13.2 MEDICATION
13.2.1 ACETAMINOPHEN
13.2.2 ANTIBIOTICS
13.2.2.1 Ciprofloxacin
13.2.2.2 Chloramphenicol
13.2.2.3 Ceftriaxone
13.2.2.4 Ofloxacin
13.2.2.5 Others
13.2.3 IMMUNOGLOBULINS
13.2.4 CORTICOSTEROIDS
13.2.5 ANTI-VIRALS
13.2.6 OTHERS
13.3 SUPPORTIVE CARE
13.4 VACCINATION
13.4.1 DENGVAXIA (CYD-TDV)
13.4.2 DENVAX (TAK-003)
13.4.3 TETRAVAX-DV
13.4.4 TDEN PIV
13.5 OTHERS
14 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY SEVERITY
14.1 OVERVIEW
14.2 UNCOMPLICATED
14.3 SEVERE
15 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLET
15.2.2 CAPSULES
15.2.3 OTHERS
15.3 PARENTERAL
15.3.1 INTRAVENOUS
15.3.2 SUBCUTANEOUS
15.3.3 OTHERS
16 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE
16.1 OVERVIEW
16.2 PRESCRIPTION
16.3 OVER THE COUNTER (OTC)
17 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY END USER
17.1 OVERVIEW
17.2 HOME HEALTHCARE
17.3 HOSPITALS
17.4 SPECIALTY CLINICS
17.5 OTHERS
18 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 RETAIL PHARMACIES
18.3 HOSPITAL PHARMACY
18.4 ONLINE PHARMACY
18.5 OTHERS
19 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY GEOGRAPHY
19.1 MIDDLE EAST AND AFRICA
19.1.1 SOUTH AFRICA
19.1.2 SAUDI ARABIA
19.1.3 UAE
19.1.4 ISRAEL
19.1.5 EGYPT
19.1.6 REST OF MIDDLE EAST & AFRICA
20 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
21 SWOT ANALYSIS
22 COMPANY PROFILE
22.1 VIATRIS INC.
22.1.1 COMPANY SNAPSHOT
22.1.2 COMPANY SHARE ANALYSIS
22.1.3 PRODUCT PORTFOLIO
22.1.4 RECENT DEVELOPMENT
22.2 PFIZER INC.
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 COMPANY SHARE ANALYSIS
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 COMPANY SHARE ANALYSIS
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENT
22.4 PERRIGO COMPANY PLC
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 COMPANY SHARE ANALYSIS
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 GLAXOSMITHKLINE PLC
22.5.1 COMPANY SNAPSHOT
22.5.2 REVENUE ANALYSIS
22.5.3 COMPANY SHARE ANALYSIS
22.5.4 PRODUCT PORTFOLIO
22.5.5 RECENT DEVELOPMENT
22.6 DR. REDDY’S LABORATORIES LTD.
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENT
22.7 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
22.8.1 COMPANY SNAPSHOT
22.8.2 REVENUE ANALYSIS
22.8.3 PRODUCT PORTFOLIO
22.8.4 RECENT DEVELOPMENTS
22.9 ABIVAX
22.9.1 COMPANY SNAPSHOT
22.9.2 PRODUCT PORTFOLIO
22.9.3 RECENT DEVELOPMENTS
22.1 AUROBINDO PHARMA
22.10.1 COMPANY SNAPSHOT
22.10.2 REVENUE ANALYSIS
22.10.3 PRODUCT PORTFOLIO
22.10.4 RECENT DEVELOPMENTS
22.11 BAXTER
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 PRODUCT PORTFOLIO
22.11.4 RECENT DEVELOPMENT
22.12 EMERGEX VACCINES
22.12.1 COMPANY SNAPSHOT
22.12.2 PRODUCT PORTFOLIO
22.12.3 RECENT DEVELOPMENTS
22.13 HIKMA PHARMACEUTICALS PLC
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENT
22.14 SANOFI
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENTS
22.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENTS
23 QUESTIONNAIRE
24 RELATED REPORTS
Lista de Tablas
LIST OF TABLES
TABLE 1 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
TABLE 3 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA MOSQUITO-TO-HUMAN TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA MOTHER-TO-CHILD TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 16 MIDDLE EAST AND AFRICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA SUPPORTIVE CARE IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 19 MIDDLE EAST AND AFRICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 21 MIDDLE EAST AND AFRICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 22 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY SEVERITY 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA UNCOMPLICATED IN DENGUE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA SEVERE IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 27 MIDDLE EAST AND AFRICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA PRESCRIPTION IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 32 MIDDLE EAST AND AFRICA OVER THE COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 33 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 35 MIDDLE EAST AND AFRICA HOSPITALS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 36 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 37 MIDDLE EAST AND AFRICA OTHERS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 38 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA DIRECT TENDER IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 40 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 41 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 42 MIDDLE EAST AND AFRICA HOSPITALS IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 43 MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICADENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 58 SOUTH AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 59 SOUTH AFRICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 60 SOUTH AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 SOUTH AFRICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 SOUTH AFRICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 SOUTH AFRICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 71 SOUTH AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 72 SAUDI ARABIA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 73 SAUDI ARABIA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 74 SAUDI ARABIA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 SAUDI ARABIA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 SAUDI ARABIA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 86 UAE DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 87 UAE DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 88 UAE DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 UAE MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 UAE ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 UAE OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 UAE VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 UAE DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 94 UAE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 95 UAE ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 UAE PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 UAE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 98 UAE DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 UAE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 100 ISRAEL DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 101 ISRAEL DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 102 ISRAEL DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 103 ISRAEL MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 ISRAEL ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 ISRAEL OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 106 ISRAEL VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 ISRAEL DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 108 ISRAEL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 109 ISRAEL ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 ISRAEL PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 111 ISRAEL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 112 ISRAEL DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 113 ISRAEL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 114 EGYPT DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 115 EGYPT DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 116 EGYPT DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 117 EGYPT MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 118 EGYPT ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 119 EGYPT OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 120 EGYPT VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 121 EGYPT DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 122 EGYPT DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 123 EGYPT ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 124 EGYPT PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 125 EGYPT DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 126 EGYPT DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 127 EGYPT DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 128 REST OF MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
Lista de figuras
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: MARKET END USER GRID
FIGURE 10 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASING INCIDENCE OF DENGUE CASES AND ADVENT OF VACCINATION PROGRAMS ARE DRIVING THE MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 FUNGAL DENGUE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET
FIGURE 15 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY STRAINS, 2020
FIGURE 16 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY STRAINS, 2020-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2021-2028)
FIGURE 18 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TRANSMISSION, 2020
FIGURE 20 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TRANSMISSION 2020-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TRANSMISSION, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TRANSMISSION, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TYPE, 2020
FIGURE 24 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 26 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY SEVERITY, 2020
FIGURE 28 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY SEVERITY , 2020-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2021-2028).
FIGURE 30 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 34 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020
FIGURE 36 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020-2028 (USD MILLION)
FIGURE 37 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2020-2028)
FIGURE 38 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY END USER, 2020
FIGURE 40 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 41 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 42 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 45 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 46 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 48 MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 49 MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 51 MIDDLE EAST & AFRICA DENGUE TREATMENT MARKET: BY STRAINS (2021-2028)
FIGURE 52 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
